Seizure and Prison for Owner of Immuno Biotec
Register now for ECA's GMP Newsletter
After a four-year investigation by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) (and with the support of the London Regional Asset Recovery Team, RART), the owner of Guernsey-based Immuno Biotech is now facing a £1.4 million seizure, including private property.
He has already served a 15-month prison sentence based on four counts of manufacturing, selling and supplying an unlicensed drug (plus one for money laundering).
Immuno Biotech was a distributor of a human blood product called Globulin component Macrophage Activating Factor (GcMAF). GcMAF was advertised and sold over the Internet as a so-called "miracle cure" for various diseases and conditions. Following an investigation, the MHRA confiscated more than 10,000 vials of the product and issued a warning to the public.
Source: GOV.UK provided by the Government Digital Service.
Related GMP News
02.10.2024MHRA: New Rules for Manufacturers and Wholesalers after Brexit
24.09.2024What is RCA (Root Cause Analysis)?
18.09.2024Lack of GMP Training and related Documentation: What Deviations can be found in FDA Warning Letters?
04.09.2024Switzerland: Changes for the Qualification of QPs (Responsible Person; RP in Switzerland)
04.09.2024Insufficient Root Cause Analysis leads to FDA Warning Letter
28.08.2024Switzerland to implement Measures to combat Shortages of Medicines